Home > Healthcare > Medical Devices > Diagnostic Devices > Legionella Testing Market

Legionella Testing Market Trends

Report ID: GMI8361
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Legionella Testing Market Trends

Technological advancements in molecular biology, microbiology, and immunology have led to the development of more sensitive, specific, and rapid Legionella testing methods.
Advanced molecular techniques such as PCR technologies and next-generation sequencing (NGS) enable the detection and identification of legionella bacteria with greater speed and accuracy compared to traditional culture methods.
Thus, these advancements in testing technology enhance diagnostic capabilities, allowing for earlier detection of legionella contamination and prompt intervention to prevent outbreaks.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global legionella testing industry was valued at USD 316.8 million in 2023 and is estimated to reach over USD 659.4 million by 2032 attributed to the increasing prevalence of pneumonia and legionella-related illnesses.

Water legionella testing industry accounted for USD 193.6 million in 2023 and will grow significantly through 2032 attributed to the heightened awareness surrounding legionella-related illnesses, such as legionnaires' disease.

North America recorded 40.6% of the legionella testing industry share in 2023 and is predicted to witness substantial growth through 2032 as the region has a robust healthcare infrastructure and regulatory framework that emphasizes the importance of legionella testing for public health and safety.

Abbott Laboratories, Becton, Dickinson & Company, Biomerieux, Bio-Rad Laboratories Inc., Danaher Corporation, IDEXX Laboratories Inc, Merck KGaA, Pro-lab Diagnostics Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc.